The appointment is effective form February 6, 2015
PerkinElmer has announced that Dr Sylvie Grégoire has been elected to its Board of Directors, effective February 6, 2015.
"It is with great enthusiasm that we welcome Dr Sylvie as the newest member of our Board. Her extensive experience gained through global leadership positions within top pharmaceutical and biotechnology companies will prove highly valuable in helping oversee the strategic direction of the company," said Mr Robert Friel, chairman and CEO, PerkinElmer.
With nearly 30 years of industry experience, Dr Grégoire most recently served as the President of Human Genetic Therapies for Shire for seven years.